Soluble insulin receptor and metabolic syndrome

The metabolic syndrome describes a group of signs that increase the likelihood for developing type 2 diabetes mellitus, cardiovascular diseases and some types of cancer. The action of insulin depends on its binding to membrane receptors on its target cells. We wonder if blood insulin could travel bound to proteins and if, in the presence of hyperinsulinemia, a soluble insulin receptor might be generated. We used young adult Wistar rats (which have no predisposition to obesity or diabetes), whose drinking water was added 20 % of sugar and that were fed a standard diet ad libitum for two and six months. They were compared with control rats under the same conditions, but that had running water for consumption. At two months, the rats developed central obesity, moderate hypertension, high triglyceride levels, hyperinsulinemia, glucose intolerance and insulin resistance, i.e., metabolic syndrome. Electrophoresis of the rats’ plasma proteins was performed, followed by Western Blot (WB) for insulin and for the outer portion of the insulin receptor. The bands corresponding to insulin and to the receptor external part were at the same molecular weight level, 25-fold higher than that of free insulin. We demonstrated that insulin, both in control animals and in those with hyperinsulinemia, travels bound to the receptor outer portion (ectodomain), which we called soluble insulin receptor, and that is released al higher amounts in response to plasma insulin increase; in rats with metabolic syndrome and hyperinsulinemia, plasma levels are much higher than in controls. Soluble insulin receptor increase in blood might be an early sign of metabolic syndrome.

Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice

Cannabinoid type 1 receptor (CB1R) inhibition tends to be one of the promising strategies for the treatment of obesity and other related metabolic disorders. Although CB1R inhibition may cause adverse psychiatric effects including depression and anxiety, the investigation of the role of peripheral CB1R on weight loss and related metabolic parameters are urgently needed. We first explored the effect of rimonabant, a selective CB1R antagonist/inverse agonist, on some metabolic parameters in high fat-diet (HFD)-induced obesity in mice. Then, real-time PCR and electrophysiology were used to explore the contribution of high voltage-activated Ca2+ channels (HVACCs), especially Cav1.1, on rimonabant's effect in skeletal muscle (SM) in HFD-induced obesity. Five-week HFD feeding caused body weight gain, and decreased glucose/insulin tolerance in mice compared to those in the regular diet group (P<0.05), which was restored by rimonabant treatment compared to the HFD group (P<0.05). Interestingly, HVACCs and Cav1.1 were decreased in soleus muscle cells in the HFD group compared to the control group. Daily treatment with rimonabant for 5 weeks was shown to counter such decrease (P<0.05). Collectively, our findings provided a novel understanding for peripheral CB1R's role in the modulation of body weight and glucose homeostasis and highlight peripheral CB1R as well as Cav1.1 in the SM as potential targets for obesity treatment.

Caracterización del metabolismo óseo mineral en pacientes con enfermedad renal crónica en hemodiálisis en el Servicio de Salud Metropolitano Sur, Santiago de Chile / Bone mineral metabolism in patients with chronic kidney disease on dialysis in Southern Metropolitan Santiago

Background: Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a condition of dialysis patients associated with both morbidity and mortality. Management is based on clinical guidelines with goals that are hard to comply with. Aim: To describe and compare biochemical variables associated with this disorder in two different time periods. Material and Methods: Revision of medical records of 814 patients (49% females) dialyzed during 2009 and 1018 patients (48% females), dialyzed during 2012 in Southern Metropolitan Santiago. Information about serum calcium, phosphorus, parathyroid hormone (PTH) and albumin was retrieved. Results: Median PTH values in 2009 and 2012 were 222.5 and 353.5 pg/ml respectively (p < 0.05). The figures for serum calcium corrected by albumin were 9.0 and 8.5 mg/dl respectively (p < 0.05). The figures for phosphorus were 4.7 and 5.0 mg/dl respectively (p < 0.05). The Calcium x Phosphorus product was 41.4 and 42.5 mg²/dl² (p < 0.05). Of note, the proportion patients with serum calcium below recommended levels (< 8.4 mg/dl) increased from 16% to 40% from 2009 to 2012. The proportion of patients with biochemical variables within recommended ranges was lower in 2012 than in 2009. Conclusions: There was a low proportion of patients with bone metabolism parameters within ranges recommended by clinical guidelines. These parameters were worst in 2012.

Association between obesity and impaired glucose tolerance in new providence adolescents as demonstrated by the HbA1c test / Asociación entre la obesidad y los trastornos de tolerancia a la glucosa entre los adolescentes de nueva providencia según lo demostrado por la prueba de HbA1c

OBJECTIVE: To explore the association between obesity and the development of impaired glucose tolerance (IGT) in Bahamian adolescents. METHODS: Eight hundred and seventy-three adolescents were randomly selected from five high schools in New Providence. Each student's weight, height, and waist and hip circumferences were recorded to determine body mass index (BMI). Individuals with BMIs above the 84th and 95th percentiles were classified as overweight and obese, respectively. Venous blood samples were collected from each subject and haemoglobin Ai c (HbAi c) levels were measured using a direct immunoassay method. The criterion established by the International Expert Committee for the diagnosis of IGT (HbA i c concentration of 6.0-6.4%) was used. An analysis of covariance was performed to evaluate the relationship between obesity and IGT, and a logistic regression analysis predicted the risk of IGT based on BMI classification. RESULTS: Of the 861 adolescents who completed the study, 15.0% were classified as overweight, 15.2% as obese and 7.9% as severely obese. The overall cumulative prevalence of IGT based on HbAi c levels was 16 100 cases per 100 000 adolescents and was greater in males than in females. Higher percentages of overweight and obese students were identified as having IGT compared with their normal-weight counterparts. An analysis of covariance with post hoc analyses revealed that severely obese males and females, respectively were almost 26 (OR = 25.54, 95%CI 9.92, 65.77) or 23 (OR = 22.96, 95% CI 9.81, 53.73) times more likely to develop IGT than their normal-weight counterparts (p < 0.005). CONCLUSION: The data show a strong positive association between IGT and obesity among Bahamian adolescents.

OBJETIVO: Explorar la asociación entre la obesidad y el desarrollo de trastornos de tolerancia a la glucosa (IGT) en los adolescentes de Bahamas. MÉTODOS: Ochocientos setenta y tres adolescentes fueron seleccionados aleatoriamente de cinco escuelas secundarias en Nueva Providencia. Se registraron peso, altura, y las circunferencias de cintura y cadera de cada estudiante, para determinar el índice de masa corporal (IMC). Las personas con IMC por encima de los percentiles 84 y 95 fueron clasificados como con sobrepeso y obesos, respectivamente. Se obtuvieron muestras de sangre venosa de cada sujeto, y se midieron los niveles de hemoglobina A 1c (HbAc utilizando un método de inmunoensayo directo. Se utilizó el criterio establecido por el Comité Internacional de expertos para el diagnóstico de IGT (concentración de HbA 1c de 6.0-6.4%). Se realizó un análisis de covarianza para evaluar la relación entre la obesidad y IGT, y un análisis de regresión logística para predecir el riesgo de IGT sobre la base de la clasificación del IMC. RESULTADOS: De los 861 adolescentes que completaron el estudio, 15.0% fueron clasificados como con sobrepeso, 15.2% como obesos, y 7.9% como extremadamente obesos. La prevalencia acumulativa general de IGT basada en los niveles de HbA 1c fue 16 100 casos por 100 000 adolescentes, y fue mayor en los varones que en las mujeres. Mayores porcentajes de estudiantes con sobrepeso y obesidad fueron identificados con IGT en comparación con sus contrapartes de peso normal. Un análisis de covarianza con análisis post-hoc reveló que los varones y hembras extremadamente obesos, respectivamente, fueron casi 26 (OR = 25.54, 95%CI 9.92, 65.77) o 23 (OR = 22.96, 95% CI 9.81, 53.73) veces más propensas a desarrollar IGT que sus contrapartes de peso normal (p < 0.05). CONCLUSIÓN: Los datos muestran una fuerte asociación positiva entre IGT y obesidad entre los adolescentes de las Bahamas.

Modelo de obesidade induzida por dieta hiperlipídica e associada à resistência à ação da insulina e intolerância à glicose / Model of high-fat diet-induced obesity associated to insulin resistance and glucose intolerance

OBJETIVO: Validar um modelo de obesidade induzida por dieta hiperlipídica, de baixo custo, fácil reprodutibilidade, que mimetizasse características observadas no humano e viabilizasse posteriores proposições terapêuticas. MATERIAIS E MÉTODOS: Dezesseis camundongos Swiss receberam dieta padrão (DP) ou dieta hiperlipídica (DH), durante 10 semanas. RESULTADOS: Embora o grupo DP tenha apresentado maior consumo de água (p < 0,01) e ração (p < 0,001), o grupo DH apresentou maior ganho de peso corpóreo (p < 0,5) e aumento de coxins adiposos (p < 0,001), favorecendo maior índice de adiposidade (p < 0,001), glicemia (p < 0,01) e área sob a curva nos testes de tolerância à insulina (p < 0,001) e à glicose (p < 0,01). CONCLUSÃO: Validou-se um modelo de obesidade induzida por dieta hiperlipídica associada à resistência à ação da insulina e à intolerância à glicose, em um período de 10 semanas.

OBJECTIVE: Validate a model of high-fat diet-induced obesity, of low cost, easy reproducibility, that could express characteristics observed in human, and would enable subsequent therapy proposals. MATERIALS AND METHODS: Sixteen Swiss mice received a standard diet (DP) or high-fat diet (DH) for 10 weeks. RESULTS: Although the DP group had greater water (p < 0.01) and feed (p < 0.001) consumption, the DH group had greater body weight (p < 0.5) and adipose tissue gain (p < 0.001), favoring higher adiposity index (p < 0.001), glucose (p < 0.01), and area under the curve in the insulin (p < 0.001) and glucose (p < 0.01) tolerance tests. CONCLUSION: A high-fat diet-induced obesity model has been validated, which was also associated with insulin resistance and glucose intolerance after a period of 10 weeks.

Uso dos antirretrovirais na gestação e seus possíveis efeitos adversos / Use of antiretroviral agents during pregnancy and their possible adverse effects

A transmissão vertical do HIV tem sido a forma de transmissão que mais sofreu redução nos últimos anos. O principal fator determinante para tal diminuição foi o uso da terapia antirretroviral de alta potência (HAART) nas gestantes infectadas. Atualmente, a taxa de transmissão vertical do HIV em países desenvolvidos está em torno de 2%. Apesar de seu efeito benéfico indiscutível, alguns estudos mostram possíveis efeitos colaterais causados pelo uso dos antirretrovirais nas gestantes e nos recém-nascidos. Entre os efeitos adversos mais frequentes, estão aqueles que podem estar presentes em qualquer paciente que use a medicação, como hipersensibilidade, toxicidade mitocondrial e lipodistrofia. No entanto, existem também os efeitos colaterais específicos do uso destas medicações durante a gestação. Vários estudos têm sido realizados para determinar a segurança dos antirretrovirais no binômio mãe e feto. Os possíveis efeitos adversos descritos pelo uso dos antirretrovirais na gestação são: resistência à insulina e o desenvolvimento de diabetes gestacional; pré-eclâmpsia; aumento de incidência de malformações congênitas; maior índice de parto pré-termo e/ou de baixo peso ao nascer. Esta revisão discute os possíveis efeitos adversos e suas consequências

HIV vertical transmission has been the route of transmission that most declined in the last years. The main factor implied in this mother-to-child-transmission reduction was the routine use of highly active antiretroviral therapy (HAART) by infected pregnant women. Currently, the HIV vertical transmission rate in developed countries is about 2%. Although there is an incontestable benefic effect of antiretroviral therapy, some studies show possible adverse effects in pregnant women and newborns after using the antiretroviral therapy. There are collateral effects that can occur in any patient using these drugs, such as hypersensitivity, mitochondrial toxicity, and lipodystrophy. However, there are other collateral effects, which are specific to the use of these drugs during pregnancy. Several authors have studied antiretroviral treatment in pregnancy to determine the safety of HAART to the mother-child binomial. The possible adverse effects caused by antiretroviral therapy use during pregnancy are: insulin resistance and the development of gestational diabetes; preeclampsia; higher incidence of congenital abnormalities; higher rates of preterm birth, and/or low-birth weight. This review discusses the possible adverse effects and their consequences

Obesidad pregestacional y riesgo de intolerancia a la glucosa en el embarazo y diabetes gestacional / Pregestational obesity and risk of glucose intolerance in pregnancy and gestational diabetes

ANTECEDENTES: La obesidad en mujeres en edad reproductiva es cada vez más frecuente y complica el embarazo aumentando el riesgo de enfermedades como la diabetes mellitus gestacional (DMG). OBJETIVO: Determinar el riesgo de presentar DMG e intolerancia a la glucosa (ITG) de acuerdo con el índice de masa corporal pregestacional (IMCPG). MÉTODO: Muestra de 489 pacientes, se clasificaron por IMCPG y se les realizó una curva de tolerancia oral a la glucosa (CTOG) de 100 g de 120 minutos. Se definió DMG con dos valores alterados en la CTOG e ITG con un solo valor alterado. Se aplicó prueba de chi cuadrada para determinar diferencia entre grupos y se obtuvo un Odds Ratio (OR), con intervalo de confianza del 95%. RESULTADOS: 9 pacientes con bajo peso, 194 con peso normal, 158 con sobrepeso y 128 con obesidad, edad gestacional promedio 31,3 ± 5,6 semanas. El 13% de las pacientes presentaron DMG, el 10,6% ITG. Las mujeres con sobrepeso presentaron un OR de 3,81 para desarrollar ITG (IC95% 1,62-8,95) y un OR de 3,7 para DMG (IC95% 1,65-8,38), mientas que las pacientes con obesidad pregestacional presentaron un OR de 6,6 para desarrollar ITG (IC95% 2,83-15,66) y un OR de 8,8 para DMG (IC95% 4,05-19,51), comparadas con mujeres con peso pregestacional normal. CONCLUSIÓN: La población mexicana tiene mayor riesgo de DMG que otras poblaciones y mayor prevalencia de sobrepeso y obesidad, por lo que se debe realizar un diagnóstico y tratamiento oportuno de DMG, previniendo complicaciones y diabetes mellitus tipo 2.

BACKGROUND: Obesity in women in reproductive age is becoming more frequent and it self complicates preg-nancy increasing the risk of diseases such as gestational diabetes mellitus (GDM). AIMS: To determine the risk of gestational diabetes mellitus (GDM) and impaired glucose tolerance (IGT) according to the pregestational body mass index (PGBMI). METHODS: Sample of 489 patients, they were classified by PGBMI and underwent an oral glucose tolerance test (OGTT) with 100 g of glucose during 120 minutes. GDM was defined with two altered valúes in the OGTT and IGT with a single altered value. A chi-square test was applied to determine difference between groups, and we obtained an Odds Ratio (OR), with a confidence level of 95%. RESULTS: 9 patients were low weight, 194 normal weight, 158 overweight and 128 obese, average gestational age 31.3 ± 5.6 weeks. 13% of the patients had GDM, 10.6% had IGT. Overweight women had an OR of 3.81 of developing IGT (95% Cl 1.62-8.95) and an OR of 3.7 of developing GDM (95% Cl 1.65-8.38), while women with prepregnancy obesity showed an OR of 6.6 of developing ITG (95% Cl 2.83-15.66) and an OR of 8.8 of developing GDM (95% Cl 4.05-19.51), all compared to women with prepregnancy normal weight. CONCLUSIONS: Mexican population has a higher risk of GDM than other populations and also a higher prevalence of overweight and obesity, so that every pregnant woman should be screening for GDM, has a diagnosis and receive treatment, preventing complications and Type 2 Diabetes.

Consequências metabólicas na SAOS não tratada / Metabolic consequences of untreated obstructive sleep apnea syndrome

A associação entre SAOS e a síndrome metabólica é reconhecida, sendo denominada síndrome Z. Os critérios para a síndrome metabólica incluem pelo menos três dos seguintes fatores: obesidade central (circunferência da cintura > 102 cm em homens e > 88 cm em mulheres); triglicérides > 150 mg/dL; HDL colesterol < 40 mg/dL em homens e < 50 mg/dL em mulheres; pressão arterial > 130/85 mmHg; e glicemia de jejum > 100 mg/dL. A obesidade central esta associada a SAOS e síndrome metabólica, havendo evidências de que a apneia do sono seja um fator de risco independente da obesidade, intolerância à glicose e resistência insulínica. Embora a obesidade central seja um fator de risco para ambas as condições, há evidências de que a apneia do sono seja um fator de risco independente para a intolerância à glicose e a resistência à insulina. Os mecanismos implicados decorrem da ativação do sistema nervoso simpático e do eixo hipotálamo-hipófise-adrenal; da ativação de fatores pró-inflamatórios, como IL-6 e TNF-α; e da diminuição dos níveis de adiponectina mediados principalmente pela hipoxemia intermitente relacionada às apneias. Apesar dessas evidências, os resultados dos estudos são controversos em relação aos benefícios do tratamento da apneia do sono com CPAP nas alterações metabólicas. Adicionalmente, os poucos estudos que abordaram a apneia do sono obstrutiva como um fator de risco para as dislipidemias apresentaram resultados discordantes. Estudos controlados, populacionais e longitudinais são necessários para esclarecer a interação entre a apneia do sono e as consequências metabólicas no sentido de se tratar adequadamente esses indivíduos.

There is a recognized association between obstructive sleep apnea syndrome and metabolic syndrome, designated syndrome Z. The criteria for metabolic syndrome include at least three of the following factors: central obesity (waist circumference > 102 cm for males and > 88 cm for females); triglycerides > 150 mg/dL; HDL cholesterol < 40 mg/dL for males and < 50 mg/dL for females; arterial blood pressure > 130/85 mmHg; and fasting glucose > 100 mg/dL. Central obesity is associated with OSAS and metabolic syndrome, and there is evidence that obstructive sleep apnea is an independent risk factor for obesity, glucose intolerance and insulin resistance. The implied mechanisms result from the activation of the sympathetic nervous system and of the hypothalamus-hypophysis-adrenal axis; activation of pro-inflammatory markers, such as IL-6 and TNF-α; and the reduction in adiponectin levels, principally triggered by intermittent hypoxemia related to apnea. Despite such evidence, the results are controversial regarding the benefits of treating sleep apnea with CPAP in the presence of these metabolic alterations. In addition, the few studies that have addressed sleep apnea as a risk factor for dyslipidemia have presented conflicting results. Population-based, longitudinal controlled studies are necessary in order to elucidate the interaction between sleep apnea and metabolic consequences so that these individuals are properly treated.

Avaliação da tolerência à glicose em crianças e adolescentes com fibrose cística / Glucose tolerance evaluation in children and adolescents with cystic fibrosis

Introdução: Cerca de 20% dos adolescentes com fibrose cística têm diabetes melito (DM) relacionado à fibrose cística (FC). O teste oral de tolerância à glicose (TOTG) tem sido utilizado para identificar alterações no metabolismo da glicose. Objetivo: O objetivo deste estudo foi identificar as alterações no metabolismo da glicose em crianças e adolescentes com FC e descrever as características clínicas e laboratoriais relacionadas à tolerância diminuída à glicose (TDG) e DM nesse grupo de pacientes. Pacientes e métodos: Foi realizado um estudo transversal envolvendo crianças e adolescentes com diagnóstico de FC em atendimento no Hospital de Clínicas de Porto Alegre. TOTG com glicose na dose de 1,75 g/kg de peso com dose máxima de 75 g foi realizado. Resultados: No total foram avaliados 58 pacientes (1,9-16,9 anos). TDG foi encontrada em 6 pacientes e presença de DM em 1, todos acima de dez anos de idade. Estes 7 pacientes foram comparados com os outros 29 pacientes de mesma faixa etária com TOTG normal. Os pacientes com o TOTG alterado eram mais velhos (14±1,2 vs. 10,6±4 anos, P<0,001), apresentaram maior tempo de duração da FC (13±2,6 vs. 9±4 anos, P<0,0006) e apresentaram maior número de internações (6 [5-16] vs. 3 [1,5-8,5], P<0,029). Conclusão: Neste estudo foi observada uma prevalência de alteração da tolerância à glicose de 12% em crianças e adolescentes com FC.

Background: About 20% of adolescents with cystic fibrosis (CF) present diabetes related to this condition. The oral glucose tolerance test (OGTT) has been used to identify alterations in glucose metabolism in these patients. Aim: The aim of this study was to identify changes in glucose metabolism in children and adolescents with CF and to describe the clinical and laboratory characteristics related to impaired glucose tolerance (IGT) and diabetes. Patients and methods: This was a cross-sectional study involving children and adolescents with cystic fibrosis (CF). An OGTT with 1.75 g glucose/kg - max 75 g was performed. Results: Fifty-eight individuals (1.9-16.9 years) were evaluated. IGT was found in six and diabetes in one; all were older than 10 years. These 7 patients were compared to the 29 with normal OGTT with the same age. The patients with altered OGTT were older (14±1.2 vs 10.6±4years, P<0.001), had longer FC duration (13±2.6 vs. 9±4 years, P<0.006), and had a higher number of hospitalizations (6 [5-16] vs 3[1.5- 8.5], P<0.029). Conclusion: In this study the prevalence of impaired glucose tolerance was 12% in children and adolescents with CF.

La preenfermedad: ¿es un aumento de riesgo o una progresión de la enfermedad? / Predisease: an increased risk or progression of the disease?

Es un término que genera confusión posiblemente porque el prefijo PRE es utilizado en español como criterio de temporalidad mientras que en inglés se usa como adjetivo para estudiar una determinada condición o al intentar dicotomizar variables continuas sobre un riesgo que también es continuo. La variación de la términología es debido a los cambios de los puntos de corte a través del tiempo, en función del riesgo. En enero 2004, la Asociación Americana de Diabetes introduce el término prediabetes para darle criterio de severidad al estadio de intolerancia a la glucosa oral y a la glisemia alterada en ayuna. Los pacientes son llamados "prediabéticos" indicando el relativo alto riesgo de desarrollar diabetes. En el año 2003, se publica en la literatura el término prehipertensión: uniendo las categorías normal y normal alta existentes previamente, porque los pacientes en esta categoría tienen dos veces mayor riesgo de progresión a hipertensión que aquellos con valores menores de presión arterial. Esta terminología aún no ha sido aceptada por todas las asociaciones por considerarlas confusa. Las pre-condiciones se denominan así por implicar mayor probabilidad de presentar la condición y un incremento del riesgo. Generan confusión en el médico y el paciente, ya que tienen una clara interpretación epidemiológica más no clínica, por eso la evaluación del paciente debe ser global y no de parámetros aislados.

Predisease is a confounding term, possibly since the pre prefix is used in Spanish as a criteria for temporality while in English is used as adjetive to stage a particular condition or to attempt dichotomizing continuous variables on an equally continuous risk. Variability in terminology is due to changes in cut points thru time, as a function of risk. In January 2204, American Diabetes Association introduced the term prediabetes to assign a severity criterion to the stage of oral glucose intolerance and increased fasting glucose. Patients with this condition are usually called prediabetic, indicating their high relative risk of developing diabetes. In 2003, the term prehypertension appeared for the first time in literature, combinig the former categories of "normal" and "normal-high", since patients in this category have a twofold higher risk of progression to hypertension than those with lower valvules of blood pressure. This terminology has not been widely accepted by all medical associations, since it has been considered as confusing. Pre-conditions have received thant name because they imply a higher probability of having the condition and an increased risk. They generate confusion in both physician and patient, since although they have a clear epidemiological interpretation, they lack a clinical one. Hence, the evaluation of the patient should be global, not following isolated parameters.

[ correlation between obesity and impaired glucose tolerance with periodontal diseases]

Numerous evidence indicates the deteriorating effects of obesity on body organs and its role in predisposition to systemic diseases such as diabetes. On the other hand, diabetes has been recognized as a risk factor for periodontal breakdown. This study aimed to determine the relationship between obesity and periodontal diseases. The second aim was to clarify if periodontal diseases make the individuals prone to impaired glucose tolerance. A total of 166 patients [age 35- 59 years] who sought dental care in Tabriz Dental Faculty were recruited in this study. Eighty three people had periodontitis in accordance with NHANES III index [test group] and the remaining who did not have periodontal disease served as the control group. The body weight [BW], height and waist circumference [WC] were measured in both of the study groups followed by fasting plasma glucose [FPG] and oral glucose tolerance test [OGTT]. Data were analyzed by student t-test and Chi-Square followed by calculating the odds ratio and Spearman correlation. All of the studied variables expressed a higher score in the test group than the control one [p<0.05]. Evaluation of the correlation of obesity [OB], overweight [OW], WC, and impaired glucose tolerance [IGT] with periodontal disease severity, revealed the highest correlation between OB [r=1 and p<0.001] and the lowest between OW [r=0.4 and p=0.07]. Regarding the association of OB, WC and OW with IGT among women, the strongest association was found in OB [odds ratio, 6.5; 95% CI, 1.26- 23.6] and the weakest was in OW [odds ratio, 0.43; 95% CI, 0.07-2.6]. These associations were similar among the males and the highest was between OB [odds ratio, 5; 95% CI, 0.82- 19.41] VS. the weakest that was observed in OW [odds ratio, 0.39; 95% CI, 0.07-2.17]. The association of obesity and periodontal disease is stronger than that with impaired glucose test. This may be attributed to different mechanisms involved in relationship between periodontal disease, obesity and diabetes

Prevalence of abnormalities of glucose metabolism in patients with polycystic ovary syndrome

Patients with polycystic ovary syndrome (PCOS) present a higher risk for abnormalities of glucose metabolism (AGM). For to study this in our population, we submitted 85 patients, with body mass index (BMI) of 28.5 ± 6.6 kg/m² and aged 25.5 ± 5.4 years old, to an oral glucose tolerance test (OGTT), and assessed the impact of BMI on the prevalence of impaired glucose tolerance (IGT) and of diabetes mellitus (DM). The states of glucose tolerance were classified considering fasting plasma glucose (FPG) according to the American Diabetes Association (ADA) criterion and plasma glucose at 120 minutes according to the Word Health Organization (WHO) criterion. According to the ADA criteria, 83.5 percent classified as normal and 16.5 percent as with AGM, with 15.3 percent presenting impaired fasting glucose and 1.2 percent DM, while according to the WHO criteria, 68.2 percent were classified as normal and 31.8 percent as with AGM, with 27.0 percent of them presenting IGT and 4.8 percent DM. Seventy-three percent of PCOS patients with IGT by WHO criterion had normal FPG by ADA criterion. The prevalence of AGM for both criteria increased with the body mass index. In conclusion, we found a higher prevalence of AGM in PCOS patients than that found in the general population, being the highest in obese patients. Glycemia at 120 minutes on the OGTT identified more patients with AGM than fasting glycemia. We recommended that the assessment of AGM must be done by the OGTT in all patients with PCOS.

Pacientes com a síndrome dos ovários policísticos (SOP) têm um risco maior para desenvolver anormalidades do metabolismo da glicose (AMG). Para avaliarmos a prevalência dessas anormalidades na nossa população, submetemos 85 pacientes, com índice de massa corporal (IMC) de 28,5 ± 6,6 kg/m² e média etária de 25,5 ± 5,4 anos, a teste de tolerância oral à glicose (TTOG). Os estados de tolerância à glicose foram classificados considerando a glicemia de jejum (GJ; American Diabetes Association - ADA) e glicemia aos 120 minutos (G120; Organização Mundial de Saúde - OMS). De acordo com a ADA, 83,5 por cento das pacientes foram normais e 16,5 por cento com AMG, com 15,3 por cento apresentando glicemia de jejum imprópria e 1,2 por cento diabetes mellitus (DM). De acordo com a OMS, 68,2 por cento foram normais e 31,8 por cento com AMG, com 27,0 por cento apresentando intolerância à glicose (IG) e 4,8 por cento DM. Observamos que 73 por cento das pacientes com IG pelos critérios da OMS apresentavam GJ normal pelos critérios da ADA. A prevalência de AMG para ambos os critérios foi maior entre as pacientes com IMC mais elevado. Conclusão: encontramos maior prevalência de AMG nas pacientes com a SOP do que na população geral, sendo mais elevada entre as pacientes obesas. Além disso, a G120 no TTOG identificou maior número de pacientes com AMG do que a GJ. Assim, recomendamos avaliação de AMG através do TTOG para todas as pacientes portadoras da SOP.

Diabetes melito: uma importante co-morbidade da fibrose cística / Diabetes mellitus in patients with cystic fibrosis

Diabetes melito relacionado à fibrose cística (DMFC) é a principal complicação extrapulmonar da fibrose cística. Atualmente, ele afeta 15-30 por cento dos adultos com fibrose cística e sua prevalência tende a aumentar com o aumento da expectativa de vida desses pacientes. Esse trabalho tem por objetivo rever a fisiopatologia, morbidade, manifestações clínicas, diagnóstico e tratamento do DMFC. Uma pesquisa bibliográfica utilizou os bancos de dados Medline e Literatura Latino-Americana e do Caribe em Ciências da Saúde, selecionando artigos publicados nos últimos vinte anos. A insulinopenia secundária à destruição de células beta pancreáticas é o principal mecanismo causal, embora a resistência insulínica também possa estar presente. O DMFC apresenta características do diabetes melito tipo 1 e tipo 2 e tem início, em média, aos 20 anos de idade. Ele pode cursar com hiperglicemia em jejum, pós-prandial ou intermitente. As alterações do metabolismo glicêmico agravam o estado nutricional, aumentam a morbidade, diminuem a sobrevida e pioram a função pulmonar. As complicações microvasculares estão presentes, porém raramente observam-se as macrovasculares. A triagem para o DMFC deve ser anual, a partir dos 10 anos de idade, através do teste de tolerância oral à glicose e, em qualquer faixa etária, se houver perda ponderal inexplicada ou sintomatologia de diabetes. Pacientes hospitalizados também devem ser investigados e receber terapia insulínica se a hiperglicemia em jejum persistir além de 48 h. A insulina é o tratamento de escolha para o diabetes com hiperglicemia em jejum. Não existe consenso quanto ao tratamento do diabetes intermitente ou sem hiperglicemia de jejum. Não há orientações de restrições alimentares. O acompanhamento deve ser multidisciplinar.

Cystic fibrosis-related diabetes (CFRD) is the principal extra-pulmonary complication of cystic fibrosis, occurring in 15-30 percent of adult cystic fibrosis patients. The number of cystic fibrosis patients who develop diabetes is increasing in parallel with increases in life expectancy. The aim of this study was to review the physiopathology, clinical presentation, diagnosis and treatment of CFRD. A bibliographic search of the Medline and Latin American and Caribbean Health Sciences Literature databases was made. Articles were selected from among those published in the last twenty years. Insulin deficiency, caused by reduced beta-cell mass, is the main etiologic mechanism, although insulin resistance also plays a role. Presenting features of type 1 and type 2 diabetes, CFRD typically affects individuals of approximately 20 years of age. It can also be accompanied by fasting, non-fasting or intermittent hyperglycemia. Glucose intolerance is associated with worsening of nutritional status, increased morbidity, decreased survival and reduced pulmonary function. Microvascular complications are always present, although macrovascular complications are rarely seen. An oral glucose tolerance test is recommended annually for patients e" 10 years of age and for any patients presenting unexplained weight loss or symptoms of diabetes. Patients hospitalized with severe diseases should also be screened. If fasting hyperglycemia persists for more than 48 h, insulin therapy is recommended. Insulin administration remains the treatment of choice for diabetes and fasting hyperglycemia. Calories should not be restricted, and patients with CFRD should be managed by a multidisciplinary team.

Balanço ácido externo em lactentes com diarréia crônica consequente à má absorçäo de glicose / External acid balance in infant with chronic diarrhea consequent to acquired glucose intolerance

Com o objetivo de compreender a instalaçäo da acidose metabólica consequente da diarréia crônica por intolerância adquirida à glicose, balanços ácidos externos foram efetuados durante a recuperaçäo de 12 lactentes desnutridos. Quando as crianças estavam ingerindo quantidades adequadas de fórmulas contendo glicose, ou seus polímeros, sete desenvolveram acidose franca e cinco näo apresentaram acidose. Os pacientes acidóticos produziram excesso de ácido comparado com o outro grupo (3,7 + 2 vs. 0,5 + 2 mEqg/Kg/dia, P<0,005). A excreçäo média de ácido foi semelhante nos dois grupos (2,9 + 2 vs. 2,7 + 2 mEq/Kg/dia), indicando uma incapacidade renal de excreçäo de ácido. O efeito resultante foi uma retençäo de H+ nos acidóticos, traduzindo um balanço ácido positivo, näo observado no outro grupo (balanço negativo): +0,8 +0,8 vs. -2,2 +0,8 mEq/Kg/dia, p<0,001. boa correlaçäo foi observada entre o balanço ácido e os parâmetros ácido-básicos do sangue. Especula-se que o balanço positivo de H+ nos acidóticos foi decorrência da produçäo ácida aumentada (que, por sua vez, foi devida ao aumento da excreçäo urinária de sais de ácidos orgânicos, e absorçäo aumentada de ânions indeterminados) e da incapacidade renal de excretar ácido, provavelmente secundária à depleçäo de potássio e fosfato